Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland

Lancet Psychiatry

Fecha de publicación: 30 de agosto de 2021

Autores: Heidi Taipale, PhD, Marco Solmi, PhD, Markku Lähteenvuo, PhD, Antti Tanskanen, PhD, Prof Christoph U Correll, PhD, Prof Jari Tiihonen, PhD

DOI: https://doi.org/10.1016/S2215-0366(21)00241-8

Background: Breast cancer is more common in female patients with schizophrenia than in the general population. It is not known whether treatment with prolactin-increasing antipsychotics contributes to increased odds of breast cancer.